This post was originally published on this site
https://i-invdn-com.investing.com/news/LYNXNPEB6U08A_M.jpg
In addition, the Company has granted the underwriter an option, exercisable within 45 days from the closing date, to purchase up to an additional 187,500 shares at the public offering price, less underwriting discounts and commissions. The shares have been approved for listing on NASDAQ Capital Market and are expected to commence trading on July 20, 2023, under the symbol “BGLC.” The offering is expected to close on or about July 24, 2023, subject to the satisfaction of customary closing conditions.
The Offering is being conducted on a firm commitment basis. Network 1 Financial Securities, Inc. is acting as the sole book-running manager for the Offering.
Ortoli Rosenstadt LLP is acting as U.S. counsel to BioNexus, and VCL Law LLP is acting as counsel to the underwriter with respect to the Offering.
A registration statement on Form S-1, as amended (File No. 333-269753) relating to the Offering was previously filed with the U. S. Securities and Exchange Commission (“SEC”) by the Company, and subsequently declared effective by the SEC on July 19, 2023. The Offering is being made only by means of a prospectus, forming a part of the registration statement. A final prospectus relating to the Offering will be filed with the SEC and will be available on the SEC’s website at www.sec.gov. Electronic copies of the final prospectus related to the Offering may be obtained, when available, from Network 1 Financial Securities, Inc., 2 Bridge Avenue, Suite 241, Red Bank, New Jersey 07701; Attention Adam Pasholk, email adampasholk@netw1.com or by calling +1 (800) 886-7007.
Before you invest, you should read the final prospectus and other documents the Company has filed or will file with the SEC for more complete information about the Company and the Offering. This press release shall not constitute an offer to sell or the solicitation of an offer to buy the securities described herein, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
